The positive early clinical data for SERP-01 supports the rationale for the Boundless Bio-Serapha merger but does not change deal terms. Monitor the effectiveness of the S-4 registration statement and the initiation of the Phase 2/3 trial, as these are key closing conditions and de-risking milestones.
Price Chart
Executive Summary
Boundless Bio (BOLD) filed a Rule 425 communication attaching a Serapha Bio press release announcing positive interim safety and efficacy data from an ongoing investigator-initiated trial of SERP-01 (YOLT-202) in alpha-1 antitrypsin deficiency (AATD). The data showed a single administration raised serum AAT above the protective threshold in all four participants, with durable correction out to 10 months and no serious adverse events. This filing is a routine M&A communication updating shareholders on Serapha's clinical progress; it does not change the terms of the pending merger between Boundless Bio and Serapha.
Key Financial Metrics
Key Facts
- Serapha announced positive interim data from an ongoing investigator-initiated trial of SERP-01 (YOLT-202) in 4 PiZZ AATD patients.
- Single administration of SERP-01 increased total serum AAT above the 11 µM protective threshold in all 4 participants.
- Durable correction out to 10 months was observed in the 45 mg cohort, with total AAT at or near the 20 µM lower limit of normal.
- No serious adverse events or treatment-related adverse events of grade 3 or higher were observed as of the data cutoff (October 15, 2026).
- Serapha expects to initiate a U.S. Phase 2/3 trial of SERP-01 in late 2026 or early 2027.
- The FDA has cleared an IND and granted orphan drug and RMAT designations for SERP-01.
- This filing does not modify the terms of the pending merger between Boundless Bio and Serapha.
Financial Impact
No financial figures provided in the filing. The data is early-stage and not designed to support regulatory approval.
Risk Factors
- The IIT is early stage, involves only 4 patients, and is not designed to support regulatory approval; results may not be predictive of later trials.
- The merger is subject to stockholder approvals, S-4 effectiveness, and Nasdaq listing approval; there is no guarantee of closing.
- Serapha faces a lawsuit from Beam Therapeutics Inc. regarding trade secret misappropriation or patent infringement relating to SERP-01.
- The combined company will need substantial additional funding for SERP-01 development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-431041 |
| Document: 0001193125-26-431041-index-headers.html | 0001193125-26-431041 |
| Document: 0001193125-26-431041-index.html | 0001193125-26-431041 |
| Document: 0001193125-26-431041.txt | 0001193125-26-431041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 425 | $2.41 | awaiting T+20 | — | $2.40 (−0.41%) |
Oct 26, 2026 1d ago | 425 | $2.45 | awaiting T+20 | — | $2.40 (−2.04%) |
Oct 8, 2026 18d ago | S-4 | $2.53 | awaiting T+20 | — | $2.40 (+5.14%) |
Aug 28, 2026 8w ago | 425 / 8-K | $2.81 $2.56 | ▼ −8.90% | ▼ −8.53% | $2.40 (−14.59%) |
Jul 8, 2026 15w ago | Insider Cluster | $2.51 $2.84 | ▲ +13.15% | ▲ +10.91% | $2.40 (−4.38%) |
Jul 6, 2026 16w ago | Insider Cluster | $2.50 $2.71 | ▲ +8.20% | ▲ +5.04% | $2.40 (−4.00%) |
Jun 29, 2026 17w ago | 3 | $2.50 $2.48 | ▼ −0.80% | ▲ +0.23% | $2.40 (−4.00%) |
May 8, 2026 24w ago | 8-K | $1.44 $1.42 | ▼ −1.39% | ▼ −1.41% | $2.40 (+66.67%) |
May 8, 2026 24w ago | Press Release | $1.44 $1.42 | ▲ +1.39% | ▲ +1.41% | $2.40 (−66.67%) |
Apr 17, 2026 27w ago | Press Release | $1.60 $1.42 | ▼ −11.25% | ▼ −15.45% | $2.40 (+50.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers